Desarrollo de nuevas formulaciones orales de naproxeno para el tratamiento de la migraña/Development of novel oral formulations of naproxen for the treatment of migraine

Abstract

Migraine is one of the most worldwide-spread health conditions. Hence, it is of pronounced interest to improve current treatments and/or develop novel treatments that would improve patients’ health.Currently, treatments can be divided into 2 modalities based on the status of the condition: acute treatments, for ongoing migraine episodes, and prophylactic treatments, as preventive treatment. Out of the large group of medicines being used as treatment, NSAIDs products are commonly used at both modalities. Within NSAIDs products, naproxen’s characteristics has shown great feasibility when used for optimizing formulation.Naproxen has been selected due to two main reasons. Firstly, its widespread use; and secondly, its potential margin of improvement, as a result of both its high starting dose (1000mg), and its slow release (Tmax 2-4h). Thus, the aspiration would be to improve both its bioavailability and the time of effect, consequently decreasing the effective dose and the time of action

Date of Award	2020
Original language	English
Awarding Institution	Universidad Complutense (Madrid)